OXURION (EBR:OXUR) | WebDisclosure

PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 15 days ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 15 days ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 15 days ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
BRIEF

published on 08/06/2025 at 18:05, 7 months 16 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF

published on 08/06/2025 at 18:05, 7 months 16 days ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE

published on 08/06/2025 at 18:00, 7 months 16 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica
PRESS RELEASE

published on 08/06/2025 at 18:00, 7 months 16 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC as per Belgian Transparency legislation. Company combines therapeutic innovation with technology for new treatments

Clinical Research Shareholding Changes Oxurion NV Therapeutic Innovation Transparency Notifications
BRIEF

published on 08/04/2025 at 18:05, 7 months 18 days ago

Oxurion Sécurise 30 M EUR Pour Diversification en Actifs Numériques

Investissement Financement Biopharmaceutique Cryptomonnaies Oxurion
BRIEF

published on 08/04/2025 at 18:05, 7 months 18 days ago

Oxurion Secures EUR 30M for Diversification into Digital Assets

Funding Investment Cryptocurrencies Biopharmaceuticals Oxurion
PRESS RELEASE

published on 08/04/2025 at 18:00, 7 months 18 days ago

Oxurion obtient une offre de financement revue à la hausse à 30 M EUR pour lancer la diversification de sa trésorerie en actifs numériques
Oxurion NV reçoit une offre de financement de 30 millions d'euros d'Atlas Special Opportunities pour investir dans Bitcoin et Ethereum. Objectif de diversification de la trésorerie

Financement Bitcoin Ethereum Oxurion NV 30 Millions D'euros

Published on 03/23/2026 at 02:00, 1 hour 18 minutes ago

FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 23:00, 2 days 4 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 5 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 6 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 13 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 8 hours 56 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 14 hours 55 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 4 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 6 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 6 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days 8 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 8 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 9 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 9 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 2 days 9 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News